Core Viewpoint - The company, Boji Pharmaceutical (300404.SZ), is a specialized CRO service provider primarily offering outsourced pharmaceutical research and development services and charging technical service fees. Currently, the company's overseas business accounts for a small proportion of its overall operations [1]. Group 1 - The company focuses on providing CRO services to pharmaceutical enterprises [1] - The primary revenue model involves charging technical service fees for its services [1] - The company's international business presence is limited at this stage [1]

Group 1 - The company, Boji Pharmaceutical, is a professional CRO service provider primarily offering outsourced pharmaceutical research and development services [1] - The company's current drug pipeline focuses on innovative drugs, including chemical drugs, biological drugs, and traditional Chinese medicine, covering various therapeutic areas [1] - Additionally, the company provides clinical trial and registration application services related to medical devices [1]

（文章来源：证券日报） 证券日报网讯 7月29日晚间，博济医药发布公告称，近日，公司获得国家知识产权局颁发的两项发明专 利证书，分别为"一种托匹司他的制备方法"和"一种鞣酸小檗碱口服制剂及其制备方法"。 ...

证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，公司有多个处于不同阶段的自研项 目，该类项目由公司自主立项，拥有自主知识产权，例如用于治疗慢性心力衰竭的中药1.2类品种"CRA （原料）"及"CRA片（制剂）"，目前已获得国家药品监督管理局核准签发的《药物临床试验批准通知 书》。 （文章来源：证券日报） ...

Group 1 - The company, Boji Pharmaceutical, is a professional CRO (Contract Research Organization) service provider [2] - It primarily offers outsourced pharmaceutical research and development services to pharmaceutical companies [2] - The company generates revenue by charging technical service fees [2]

（文章来源：证券日报） 证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，截至2024年度，公司累计与900余家 临床试验服务机构开展合作，大部分三甲医院均有合作过。 ...

（文章来源：证券日报） 证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，公司服务客户众多，以国内中大型 医药企业为主，服务过的医药企业超过两千家。 ...

Core Viewpoint - The company, Boji Pharmaceutical, reported that its subsidiary, Jiutai Medical Equipment, is successfully engaged in clinical trials and registration services related to medical devices [2] Company Summary - Boji Pharmaceutical's subsidiary, Jiutai Medical Equipment, is primarily focused on clinical trials and registration application services for medical devices [2] - The company indicated that all business operations are progressing smoothly [2]

Core Viewpoint - The company Boji Pharmaceutical (300404) is actively engaged in providing research and development services for Alzheimer's disease medications [1] Group 1 - The company responded to investor inquiries on July 29, indicating its involvement in Alzheimer's drug development [1]

证券代码：300404 证券简称：博济医药 公告编号：2025-061 博济医药科技股份有限公司 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的两项发明专利证书，具体情况如下： 一、专利基本情况 | 序号 | 发明名称 | 专利权人 | 证书号 | 专利号 | 专利申请日 | | | 授权公告日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种托匹司他的 | 博济医药科 技股份有限 | 第8116481号 | ZL 2023 1 | 2023 | 年 08 | 2025 | 年 07 | | | 制备方法 | 公司 | | 0988381.8 | 月 07 | 日 | 月 | 29 日 | | 2 | 一种鞣酸小檗碱 | 博济医药科 | | ZL 2024 1 | 2024 | 年 11 | 2025 | 年 07 | | | 口服制剂及其制 | 技股份有限 | 第8116823号 | 1565449.2 | 月 05 | 日 | 月 | 29 日 | | | 备方法 | 公司 | | | | | ...